Navigation Links
Scientists Uncover New Weapon Against Huntington's
Date:4/3/2009

Treatment could save brain cells from ravages of neurodegenerative disease

FRIDAY, April 3 (HealthDay News) -- Harvard scientists say they've found a possible way to prevent brain cells from falling victim to the ravages of Huntington's disease.

The work is still in the preliminary stages, and the researchers don't know if the strategy will work in humans. Still, a Huntington's disease expert said the findings could lead to a way to combat the incurable condition.

"They suggest a new way that you could approach developing treatments. I think it's going to emerge as a theme," said University of California at Irvine professor Leslie Thompson.

Huntington's disease is inherited, and children of parents with a single faulty gene have at least a 50 percent chance of developing it. The condition typically develops in middle age, causing the body to move involuntarily, leading to symptoms such as balance and coordination problems, slurred speech, swallowing problems and dementia.

Death typically occurs within 10 to 30 years.

There's no treatment to stop the progression of Huntington's disease or cure it, although patients can take drugs to control their symptoms.

"It's like when you have a rotten tooth," said study co-author Dr. Dimitri Krainc. "You can take painkillers so you don't feel the pain, but the tooth is still rotten."

Krainc, an associate professor of neurology at Harvard Medical School, and his colleagues tried to find a way to reduce the build-up of proteins in brain cells stricken by the disease.

Essentially, Krainc said, proteins pile up in the cells and cause problems. "It's like trash that doesn't get picked up in a crowded apartment," he said, "If you don't remove trash, it eventually suffocates you."

Indeed, clogged cells either stop functioning properly or die, Thompson said.

In the new study, the researchers tinkered with the troublesome proteins through genetic modification. They report their findings in the April 3 issue of Cell.

According to Krainc, the researchers found that their approach allowed proteins within the cells to degrade as they're supposed to. The strategy worked in worms, mice and the brain cells taken from dead people.

Drugs known as HDAC inhibitors have the same effect and are already being tested as treatments for Huntington's disease and cancer, Krainc said. The drugs are currently used to treat psychiatric disorders.

There are many unknowns, however. Researchers don't know whether the treatment will work in humans, and the potential costs of drugs are unclear.

Still, research may take a matter of years, not decades, Krainc said.

In the big picture, the new research "could have broad implications for a number of neurodegenerative diseases," Thompson said.

Alzheimer's disease, for example, is also caused when cells become clogged and fail to function properly.

"It's an extremely exciting and promising area of research," Thompson said, "and new and novel."

More information

To learn more about Huntington's disease, try the U.S. National Institutes of Health.



SOURCES: Dimitri Krainc, M.D., Ph.D., professor, neurology, Harvard Medical School, Boston; Leslie Thompson, Ph.D., professor, psychiatry and human behavior, University of California at Irvine; April 3, 2009, Cell


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists Uncover New Weapon Against Huntington's
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection of ... “Wilderness Voices” is the creation of published author, Martha McKown, an ordained United ... inspired as a very young child when her older sisters studied High School literature. ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s ... of published author, Julianne Hale, a consultant for the Intelligence Community. For ... focusing on the Near East region. Julianne has written hundreds of reports ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... Stewart is the Founder and Managing Member for t4 Leadership Development & Consulting. ... critical to his definition of “success”: physician leadership development, servant leadership, data driven ...
(Date:8/22/2017)... ... ... “Call Of Spiritual Duty”: a revelation in an era defined by intentional ... Growing up on the streets of North Visalia, California, Carlos Lizarde quickly became familiar ... keys to his life, he noticed immediately that opportunities and blessings began to shift ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that ... healthcare employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: